home / stock / cfrx / cfrx news

CFRX News and Press, ContraFect Corporation From 09/18/23

Stock Information
Company Name: ContraFect Corporation
Stock Symbol: CFRX
Market: NASDAQ
Website: contrafect.com
Menu
CFRX CFRX Quote CFRX Short CFRX News CFRX Articles CFRX Message Board
Get CFRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CFRX - ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investiga...
CFRX - ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S...

CFRX - Contrafect GAAP EPS of -$1.94 misses by $0.13

2023-08-14 12:49:01 ET Contrafect press release ( NASDAQ: CFRX ): Q2 GAAP EPS of -$1.94 misses by $0.13 . As of June 30, ContraFect had cash and cash equivalents of $14.4M. For further details see: Contrafect GAAP EPS of -$1.94 misses by $0.13

CFRX - ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment...
CFRX - ContraFect enters a warrant exercise transaction for $9.6M

2023-06-27 10:17:49 ET A clinical-stage biotechnology company, ContraFect ( NASDAQ: CFRX ) enters into a warrant exercise agreement with an existing accredited investor to purchase 7M shares. In connection with the exercise, the company also agreed to reduce the exercis...

CFRX - ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of l...

CFRX - ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of l...
CFRX - Top Penny Stocks Trading Mistakes to Avoid 

2023-06-12 06:00:00 ET 3 Mistakes That Penny Stocks Traders Make The allure of penny stocks lies in their affordable price and high growth potential. Typically priced under $5 per share, penny stocks present an opportunity for substantial returns, even for investors operating with limit...

CFRX - Penny Stocks Trading and Options: Strategies for Leveraged Profits 

2023-06-11 11:00:00 ET 3 Tips for Options Trading With Penny Stocks Penny stocks, low-priced securities of small-cap companies, offer a unique investment landscape brimming with high-growth potential. Their lower price point allows for a wider range of investment possibilities, includin...

CFRX - CVNA, BARK and MRKR among mid-day movers

2023-06-09 14:37:00 ET Gainers: Blue Apron Holdings ( APRN ) +65% . Sientra ( SIEN ) +50% . ContraFect ( CFRX ) +43% . Global Indemnity ( GBLI ) +23% . Disc Medicine Opco ( IRON ) +21% . Olema Pharmaceuticals ( OLMA ) +...
Previous 10 Next 10